STOCK TITAN
  1. Home
  2. Sec-filings
  3. BBIO
  4. [Form 4] BridgeBio Pharma, Inc. Insider Trading Activity

BridgeBio Pharma (BBIO) CEO discloses RSU vesting and stock sales

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

BridgeBio Pharma's chief executive officer and director reported multiple stock transactions in December 2025. On December 12, 2025, 60,975 restricted stock units converted into common stock, and 30,964 shares were withheld to satisfy tax obligations linked to this vesting.

On December 15, 2025, the officer sold 28,311 shares at a weighted average price of $74.5997 and 1,700 shares at $75.2412 under a Rule 10b5-1 sales plan adopted on March 31, 2025. After these transactions, the officer directly owned 228,776 shares, with an additional 755,686 and 4,558,447 shares held indirectly through family trusts, subject to a disclaimer of beneficial ownership beyond any pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider Kumar Neil
Role Chief Executive Officer
Sold 30,011 shs ($2.24M)
Type Security Shares Price Value
Sale Common Stock 28,311 $74.5997 $2.11M
Sale Common Stock 1,700 $75.2412 $128K
Exercise Restricted Stock Units 60,975 $0.00 --
Exercise Common Stock 60,975 $0.00 --
Tax Withholding Common Stock 30,964 $75.15 $2.33M
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 230,476 shares (Direct); Restricted Stock Units — 60,976 shares (Direct); Common Stock — 755,686 shares (Indirect, By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.)
Footnotes (1)
  1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 60,975 shares of Common Stock underlying the Reporting Person's RSUs. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. Represents the weighted average sale price of the shares sold from $74.12 to $75.11 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $75.13 to $75.49 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. The RSUs vest with respect to 1/2 of the underlying shares on December 12, 2025. Thereafter, the remaining underlying shares shall vest on December 12, 2026, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kumar Neil
(Last) (First) (Middle)
C/O BRIDGEBIO PHARMA, INC.
3160 PORTER DR., SUITE 250
(Street)
PALO ALTO CA 94304
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/12/2025 M 60,975 A (1) 289,751 D
Common Stock 12/12/2025 F 30,964(2) D $75.15 258,787 D
Common Stock 12/15/2025 S(3) 28,311 D $74.5997(4) 230,476 D
Common Stock 12/15/2025 S(3) 1,700 D $75.2412(5) 228,776 D
Common Stock 755,686 I By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(6)
Common Stock 4,558,447 I By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(6)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 12/12/2025 M 60,975 (7) (7) Common Stock 60,975 $0 60,976 D
Explanation of Responses:
1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
2. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 60,975 shares of Common Stock underlying the Reporting Person's RSUs.
3. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.
4. Represents the weighted average sale price of the shares sold from $74.12 to $75.11 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
5. Represents the weighted average sale price of the shares sold from $75.13 to $75.49 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
6. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
7. The RSUs vest with respect to 1/2 of the underlying shares on December 12, 2025. Thereafter, the remaining underlying shares shall vest on December 12, 2026, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
Remarks:
/s/ Will Solis, Attorney-in-Fact 12/16/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider stock transactions did BridgeBio Pharma's CEO report on 12/12/2025?

On December 12, 2025, the chief executive officer reported that 60,975 restricted stock units converted into common stock. In connection with this vesting, 30,964 shares of BridgeBio Pharma common stock were withheld to satisfy the officer's tax obligations.

What share sales did the BridgeBio Pharma (BBIO) CEO make on 12/15/2025?

On December 15, 2025, the CEO sold 28,311 shares of BridgeBio Pharma common stock at a weighted average price of $74.5997 per share and an additional 1,700 shares at a weighted average price of $75.2412 per share. These sales were executed under a Rule 10b5-1 sales plan.

How many BridgeBio Pharma shares does the CEO own after these transactions?

Following the reported transactions, the chief executive officer directly owned 228,776 shares of BridgeBio Pharma common stock. In addition, 755,686 shares were held through the Kumar Haldea Family Irrevocable Trust and 4,558,447 shares through the Kumar Haldea Revocable Trust, with beneficial ownership of these trust-held shares disclaimed except to the extent of any pecuniary interest.

Were the BridgeBio Pharma CEO's stock sales made under a Rule 10b5-1 plan?

Yes. The filing states that the December 15, 2025 stock sales were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on March 31, 2025. Rule 10b5-1 plans are pre-arranged trading programs for buying or selling securities.

What do the CEO's restricted stock units (RSUs) in BridgeBio Pharma represent?

Each restricted stock unit (RSU) represents a contingent right to receive one share of BridgeBio Pharma common stock. The RSUs vest with respect to one-half of the underlying shares on December 12, 2025, with the remaining underlying shares vesting on December 12, 2026, subject to the CEO's continued service. The RSUs have no expiration date.